Profile / RNA Medicine
Örn
Almarsson
A vaccine is only as good as the truck that carries it. He spent thirty years building better trucks.
Örn Almarsson, Co-Founder & CEO, Axelyf
A vaccine is only as good as the truck that carries it. He spent thirty years building better trucks.
Ask a room full of biologists what stops a good RNA drug from working and most will reach for the molecule. Örn Almarsson reaches for the delivery. The gene-editing instruction can be flawless; if the nanoparticle carrying it dumps its cargo in the liver and nowhere else, the medicine never arrives. That gap - between a brilliant payload and the place it actually needs to go - is the problem he has built an entire career, and now a company, around.
Today he is co-founder and CEO of Axelyf, a small Icelandic-American biotech in the Boston area trying to do something the field has mostly failed at: steer lipid nanoparticles past the liver and into tissues that have stayed stubbornly out of reach. He is doing it with a proprietary lipid library, a machine-learning model he named ANNA, and the conviction that the science is the easy part.
Axelyf's pitch is deceptively narrow. RNA medicines - the mRNA vaccines, the gene editors, the silencers - all depend on a fatty bubble called a lipid nanoparticle to ferry fragile genetic cargo into cells. Get the lipid chemistry right and the medicine reaches its target intact. Get it wrong and the dose either fails or sets off the kind of inflammation that makes patients miserable.
The company's AXL platform pairs custom chemical modifications with rational particle design to build nanoparticles that aim beyond the liver while staying tolerable. Sitting on top of it is ANNA - the Artificial Network for Nanoparticle Assessment - a machine-learning model that designs candidate lipid structures and predicts how they will behave before anyone pipettes a thing. It is, in effect, a chemist that never sleeps and never runs out of ideas.
There is a second thread to the work, and it is the one with the better story. Alongside the RNA-delivery lipids, Axelyf is developing anti-inflammatory therapies built around astaxanthin - the natural antioxidant produced by microalgae. It is the same pigment that turns wild salmon pink. A molecule most people have only ever met on a dinner plate became the seed of a drug pipeline for autoimmune and inflammatory conditions.
The current frontier, by his own description, is the hardest one of all. Almarsson is working with a chemistry team at an Irish university on surface modifications that would redirect nanoparticles toward the brain - the organ where biologics and RNA have so far been almost useless.
"The rate-limiting factor is delivery. The challenge is determining where to direct them and how to deliver them."
He pushes back on the cult of the noble failure. "Failure teaches you less than success," he says - failure is a learning opportunity that demands adaptability, not a trophy.
He credits Colin Gardner, a former Merck R&D leader, as a trusted advisor and friend - and makes a point of paying that kind of support forward.
Use ChatGPT and its cousins, he advises - but with critical thinking, and then go check the answer with a real expert.
The reading list says a lot about the wiring. Malcolm Gladwell's Revenge of the Tipping Point. Jonah Berger's The Catalyst: How to Change Anyone's Mind. And, fittingly, Nobel laureate Tom Cech's The Catalyst: RNA and the Quest to Unlock Life's Deepest Secrets. Two books about persuasion, one about RNA - which is more or less the job description of a scientist-founder.
The pattern that recurs in interviews is pragmatism. He is allergic to the idea that elegant science wins on elegance alone. A drug that physicians won't prescribe and payers won't cover is, to him, not really a drug. It is a paper. That tension - beautiful chemistry versus the messy economics of medicine - is the thing he keeps circling back to, and it is what separates Axelyf's framing from a hundred other delivery startups.
The antioxidant at the heart of Axelyf's anti-inflammatory work, astaxanthin, is the very pigment that turns wild salmon pink. Dinner became a drug pipeline.
He holds over 60 patents - more than most working scientists ever publish in articles. The man makes things, not just findings.
He thinks the brain is the last great frontier for RNA and gene editing - and he is spending lab hours trying to get nanoparticles there.
Axelyf's lipid-designing model has a name and a personality: ANNA, the Artificial Network for Nanoparticle Assessment.
Solve delivery, and you unlock every RNA medicine waiting behind it.
The ambition is not a single drug. It is a key - lipids that go where the field can't yet send them, and anti-inflammatory therapies that doctors will actually reach for.
Sources: Axelyf, Synthace, Inside Precision Medicine, BioTechniques, RNA-Seq Blog, CRISPR Medicine News, A Dose of Reality podcast.